Allergan Announces the Latisse Make a Wish Campaign

The Make a Wish Foundation is a great charity and nice that there’s more money coming in through donations.   I watched the video with the
announcement of the Latisse prescription drug to create longer eyelashes and it looked liked a miniature red carpet event for the Oscars, not even really looking at lashes but focused on the dresses they wore and chit chat conversations for most of the video, just somewhat different or odd. 
We get longer eye lashes and enroll in LashPerks, and Make a Wish benefits it appears.   Blowing on an eyelash and making a wish is the theme.  BD 
“For every person who registers for our rewards program LATISSE™ LashPerks, from now through December 31, 2009, Allergan will contribute an additional $5 to the Make-A-Wish Foundation, up to $500,000. Best of all, your participation will help grant the wishes of children with life-threatening medical conditions in your community.”
(IRVINE, Calif., March 27, 2009) /PRNewswire/ — Allergan, Inc. (NYSE: AGN) hosted a star-studded event last night in Hollywood to launch
, a charitable public awareness campaign designed to help make wishes come true. Actress Brooke Shields and beauty expert to the stars Anastasia Soare will lead the campaign to generate $1 million to support the Make-A-Wish Foundation, a non-profit organization dedicated to granting the wishes of children with life-threatening medical conditions.
(bimatoprost ophthalmic solution) 0.03%, the first and only science-based prescription treatment approved by the U.S. Food and Drug Administration for hypotrichosis of the eyelashes (inadequate or not enough lashes) that is used to grow eyelashes, making them longer, fuller and darker.
With the help of generous donors and nearly 25,000 volunteers, the Make-A-Wish Foundation grants a wish every 40 minutes and has granted more than 174,000 wishes in the United States since its inception. For more information about the Make-A-Wish Foundation, visit
.

ducknetweb.blogspot.com

Tags: , , , , ,

Leave a Reply